Researchers developed a model to predict severe acute kidney injury in patients receiving cisplatin, a chemotherapy agent, to improve treatment outcomes and patient selection. The study examined data from six major US cancer centers and identified risk factors for cisplatin-associated acute kidney injury (CP-AKI). The model showed consistent discrimination and effectiveness in identifying patients at risk for adverse kidney events. The study also found a correlation between CP-AKI severity and reduced survival rates, emphasizing the need for accurate risk prediction in cisplatin therapy. The model incorporated readily available variables and highlighted the importance of enhancing patient care and outcomes in this treatment.
Source link
New model predicts kidney injury risk in cancer patients on cisplatin
